glp 1 and gip agonist The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GI Adverse Effects of Glucagon-Like
Description
In contrast to the case reports on altered renal function seen with exenatide, a pooled analysis of 5,594 participants from 19 randomized, controlled clinical trials of exenatide twice-daily (5 g and 10 g) showed that renal impairment-related adverse events, including acute renal failure, were rare (1.6 per 100 person-years for both groups)
No listed prices for brand-name meds and limited availability make it less ideal for those outside the insurance system
The questionnaire was revised for each round of voting based on discussions during the previous video conference call
OAT, organic anion transporter
